288 related articles for article (PubMed ID: 25293519)
1. Zoledronic acid increases cytotoxicity by inducing apoptosis in hormone and docetaxel-resistant prostate cancer cell lines.
Varol U; Degirmenci M; Karaca B; Atmaca H; Kisim A; Uzunoglu S; Sezgin C; Sanli UA; Uslu R
Tumour Biol; 2015 Feb; 36(2):779-86. PubMed ID: 25293519
[TBL] [Abstract][Full Text] [Related]
2. Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A.
Cirak Y; Varol U; Atmaca H; Kisim A; Sezgin C; Karabulut B; Uzunoglu S; Uslu R; Karaca B
BJU Int; 2012 Dec; 110(11 Pt C):E1147-54. PubMed ID: 22882676
[TBL] [Abstract][Full Text] [Related]
3. Zoledronic acid increases docetaxel cytotoxicity through pMEK and Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell line.
Fabbri F; Brigliadori G; Carloni S; Ulivi P; Vannini I; Tesei A; Silvestrini R; Amadori D; Zoli W
J Transl Med; 2008 Aug; 6():43. PubMed ID: 18691406
[TBL] [Abstract][Full Text] [Related]
4. Regulation of growth factors in hormone- and drug-resistant prostate cancer cells by synergistic combination of docetaxel and octreotide.
Erten C; Karaca B; Kucukzeybek Y; Gorumlu G; Cengiz E; Gul MK; Atmaca H; Uzunoglu S; Karabulut B; Sanli UA; Uslu R
BJU Int; 2009 Jul; 104(1):107-14. PubMed ID: 19191785
[TBL] [Abstract][Full Text] [Related]
5. Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid.
Ullén A; Lennartsson L; Harmenberg U; Hjelm-Eriksson M; Kälkner KM; Lennernäs B; Nilsson S
Acta Oncol; 2005; 44(6):644-50. PubMed ID: 16165924
[TBL] [Abstract][Full Text] [Related]
6. Zoledronic acid effects interleukin-6 expression in hormone-independent prostate cancer cell lines.
Asbagh LA; Uzunoglu S; Cal C
Int Braz J Urol; 2008; 34(3):355-63; discussion 364. PubMed ID: 18601766
[TBL] [Abstract][Full Text] [Related]
7. Enhanced cytotoxicity and apoptosis by thymoquinone in combination with zoledronic acid in hormone- and drug-resistant prostate cancer cell lines.
Dirican A; Erten C; Atmaca H; Bozkurt E; Kucukzeybek Y; Varol U; Oktay Tarhan M; Karaca B; Uslu R
J BUON; 2014; 19(4):1055-61. PubMed ID: 25536616
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells.
Karabulut B; Erten C; Gul MK; Cengiz E; Karaca B; Kucukzeybek Y; Gorumlu G; Atmaca H; Uzunoglu S; Sanli UA; Baran Y; Uslu R
Cell Biol Int; 2009 Feb; 33(2):239-46. PubMed ID: 19103299
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of docetaxel-induced cytotoxicity and apoptosis by all-trans retinoic acid (ATRA) through downregulation of survivin (BIRC5), MCL-1 and LTbeta-R in hormone- and drug resistant prostate cancer cell line, DU-145.
Kucukzeybek Y; Gul MK; Cengiz E; Erten C; Karaca B; Gorumlu G; Atmaca H; Uzunoglu S; Karabulut B; Sanli UA; Uslu R
J Exp Clin Cancer Res; 2008 Sep; 27(1):37. PubMed ID: 18789152
[TBL] [Abstract][Full Text] [Related]
10. The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer.
Morgan C; Lewis PD; Jones RM; Bertelli G; Thomas GA; Leonard RC
Acta Oncol; 2007; 46(5):669-77. PubMed ID: 17562444
[TBL] [Abstract][Full Text] [Related]
11. Weekly docetaxel and zoledronic acid every 4 weeks in hormone-refractory prostate cancer patients.
Bertelli G; Heouaine A; Arena G; Botto A; Garrone O; Colantonio I; Occelli M; Fea E; Giubergia S; Merlano M
Cancer Chemother Pharmacol; 2006 Jan; 57(1):46-51. PubMed ID: 16001175
[TBL] [Abstract][Full Text] [Related]
12. Effects of zoledronic acid and docetaxel on small GTP-binding proteins in prostate cancer.
Jones RM; Morgan C; Bertelli G
Tumour Biol; 2015 Jun; 36(6):4861-9. PubMed ID: 25631751
[TBL] [Abstract][Full Text] [Related]
13. Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical Trial.
James ND; Pirrie SJ; Pope AM; Barton D; Andronis L; Goranitis I; Collins S; Daunton A; McLaren D; O'Sullivan J; Parker C; Porfiri E; Staffurth J; Stanley A; Wylie J; Beesley S; Birtle A; Brown J; Chakraborti P; Hussain S; Russell M; Billingham LJ
JAMA Oncol; 2016 Apr; 2(4):493-9. PubMed ID: 26794729
[TBL] [Abstract][Full Text] [Related]
14. The TORC1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone-refractory prostate cancer cells.
Gravina GL; Marampon F; Petini F; Biordi L; Sherris D; Jannini EA; Tombolini V; Festuccia C
Endocr Relat Cancer; 2011 Aug; 18(4):385-400. PubMed ID: 21551258
[TBL] [Abstract][Full Text] [Related]
15. Regulation of apoptosis-related molecules by synergistic combination of all-trans retinoic acid and zoledronic acid in hormone-refractory prostate cancer cell lines.
Karabulut B; Karaca B; Atmaca H; Kisim A; Uzunoglu S; Sezgin C; Uslu R
Mol Biol Rep; 2011 Jan; 38(1):249-59. PubMed ID: 20349282
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel with or without zoledronic acid for castration-resistant prostate cancer.
Pan Y; Jin H; Chen W; Yu Z; Ye T; Zheng Y; Weng Z; Wang F
Int Urol Nephrol; 2014 Dec; 46(12):2319-26. PubMed ID: 25224665
[TBL] [Abstract][Full Text] [Related]
17. TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.
James N; Pirrie S; Pope A; Barton D; Andronis L; Goranitis I; Collins S; McLaren D; O'Sullivan J; Parker C; Porfiri E; Staffurth J; Stanley A; Wylie J; Beesley S; Birtle A; Brown J; Chakraborti P; Russell M; Billingham L
Health Technol Assess; 2016 Jul; 20(53):1-288. PubMed ID: 27434595
[TBL] [Abstract][Full Text] [Related]
18. Additive/synergistic anti-tumoral effects of the combination of docetaxel and zoledronic acid on prostate cancer cells: possible mechanisms?
Ural AU; Avcu F
Acta Oncol; 2006; 45(4):491-2. PubMed ID: 16760189
[No Abstract] [Full Text] [Related]
19. GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells.
Karanika S; Karantanos T; Kurosaka S; Wang J; Hirayama T; Yang G; Park S; Golstov AA; Tanimoto R; Li L; Thompson TC
Mol Cancer; 2015 Jun; 14():122. PubMed ID: 26084402
[TBL] [Abstract][Full Text] [Related]
20. Estradiol impairs the antiproliferative and proapoptotic effect of Zoledronic acid in hormone sensitive breast cancer cells in vitro.
Gschwantler-Kaulich D; Weingartshofer S; Grunt TW; Mairhofer M; Tan Y; Gamper J; Singer CF
PLoS One; 2017; 12(9):e0185566. PubMed ID: 28945801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
